Well Lead’s IPO Approved JD Capital Assisted 31 Companies Went Public in 2014

2015-01-05

2015 came along with good news. Well Lead Medical’s application for the Initial Public Offering (IPO) was approved by the China Securities Regulatory Commission (CSRC) on December 31, 2014.2Pd九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Founded in 2014, Well Lead is a leading supplier of medical catheters, focusing on the R&D, production and sales of catheters for anesthesia, urology, respiration and hemodialysis. Main products including trachea cannula, indwelling catheter, laryngeal mask and hemodialysis catheter are widely used in surgeries, therapy, emergency treatment and clinical care. Particularly, the production and sales of trachea cannula and indwelling catheter are well known both at home and abroad. As a domestic bellwether in medical catheters, Well Lead has obtained the ISO13485 certificate of quality system, nine registered products with the FDA (510K), 60 registered products with the European CE certification, as well as 75 domestic and 21 Canadian registration certificates for medical equipment products. For seven years in a row, Well Lead has been recognized as an annual “Category-A Enterprise of Quality Credit” by Guangdong Food and Drug Administration.2Pd九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

With products sold to over 70 countries and regions, Well Lead has entered mainstream markets like North America, Europe and Japan, where market share is high and regulation is stringent. In China, its products are used in over 300 first-class hospitals. JD fund became a shareholder of Well Lead in 2011 and owned 8% of its shares prior to public issuance.2Pd九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

In 2014, 29 of JD invested companies managed to go public in the capital market. In addition to the five A-share projects which brought 10x account return—namely UTour International Travel Service (002707), Feitian Technologies (300386), iDear-Hanyu Electrical Joint-Stock (300403), Fangsheng Pharmaceutical (603998) and Liuzhou Pharmaceutical (603368), another five companies (Banghe Pharmaceutical, Golden Monkey, Beijing Sheenline Technology, Sino Great Wall and Jiahua Energy Chemical Industry) also went public at home or abroad through M&A and back-door listing. Limin Chemical, Ideal Jewelry and Well Lead have been approved for IPO and are awaiting issuance. Among JD Capital’s investment, 18 companies have been listed on the National Equities Exchange and Quotations (NEEQ).2Pd九鼎投资(600053.SH)_上交所私募股权投资领域上市公司


2Pd九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

EN | CN